Advanced search
Publication Cover
Expert Review of Anticancer Therapy Latest Articles
Submit an article Journal homepage
57
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

Viria Becciaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Daniela Arduinia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Roberto Iacovellia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy;b Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyCorrespondence[email protected]
View further author information
,
Alessandro Scalaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Denis Occhipintia Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Chiara Ligatoa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Luigi Rocaa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, ItalyView further author information
,
Pierluigi Russoc Department of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information
,
Nazario Foschic Department of Urology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information
,
Giampaolo Tortoraa Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy;b Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyView further author information
&
Chiara Ciccareseb Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyView further author information
 show all
Received 16 Feb 2024, Accepted 17 Jun 2024, Published online: 27 Jun 2024
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

ABSTRACT

In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage. On the contrary, the results from CheckMate 914 trial showed the lack of benefit of adjuvant nivolumab. In the metastatic setting, the longer-term follow-up data of the CheckMate 9ER and CheckMate 214 trials reassessed the undoubtable role of ICI-based combination in first-line treatment, with a clear survival advantage in the subgroup of patients at intermediate/poor IMDC prognosis. No OS advantage was seen in favorable IMDC risk group patients. This 2024 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized therapy for RCC patients.

Declaration of Interest

C Ciccarese is an occasional consultant for Ipsen, Janssen, MSD, Merck, Pfizer, and Astellas and is supported by cancer research AIRC – MFAG, Rif. 29275. R Iacovelli is an advisory board member for Astellas, BMS, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, and Sanofi, and a consultant for Astellas, Eisai, MSD, and Pfizer. G Tortora reports being a consultant for BMS, MSD, Astra Zeneca, Servier, Merck Serono, Dompé. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 786.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.